User:AngsKB/sandbox

Professor Pamela Kearns MBChB, BSc (Hons), PhD, FRCPCH, focuses on the development of new therapies for refractory childhood leukaemias and lymphomas.

She is Professor of Clinical Paediatric Oncology in the Institute of Cancer and Genomic Sciences, University of Birmingham and an Honorary Consultant at the Birmingham Children’s Hospital. She is Director of the Cancer Research UK Clinical Trials Unit in the School of Cancer Sciences. She is President Elect for European Society of Paediatric Oncology (SIOP-E) and is on the Executive Board of the academic consortium 'Innovative Therapies for Children with Cancer' (ITCC).

Education

Pamela Kearns attended the University of Aberdeen where she was awarded a BSc Hons degree in Physiology. Still in Aberdeen she went on to study Medicine. In Newcastle upon Tyne she trained as a paediatric oncologist, where she undertook her doctoral project investigating the role of glutathione and glutathione S transferases in chemo-resistance in childhood acute lymphoblastic leukaemia.

Career

After completion of her clinical training and PhD, she was appointed as a Clinical Senior Lecturer in Paediatric Oncology at the University of Bristol and Honorary Consultant Paediatric Oncologist at the Bristol Children’s Hospital.

In 2007, Professor Kearns continued her translational research in resistant childhood acute leukaemias and lymphomas at the University of Birmingham.

Research

Key publications

Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U3,4, Swales KE, Tall JR, Moore AS, Toguchi M5, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J.  A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatr Blood Cancer. 2016 Dec 1 doi:10.1002/pbc.2635 [Epub ahead of print]

Main C, Stevens SP, Bailey S, Phillips R, Pizer B, Wheatley K, Kearns PR, English M, Wilne S, Wilson JS. The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis. Syst Rev. 2016 Aug 31;5(1):143. doi: 10.1186/s13643-016-0318-1

Main C, Dandapani M, Pritchard M, Dodds R, Stevens SP, Thorp N, Taylor RE, Wheatley K, Pizer B, Morrall M, Phillips R, English M, Kearns PR, Wilne S, Wilson JS. The effectiveness and safety of proton beam radiation therapy in children with malignant central nervous system (CNS) tumours: protocol for a systematic review. Syst Rev. 2016 Jul 27;5(1):124. doi: 10.1186/s13643-016-0285-6.

Pearson ADJP, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner B, Capdeville R, Caron H, Carleer J, Chesler L, Geoerger  B, Kearns P, Marshall LV, Pfister SM, Schleiermacher G, Skolnik J, Spadoni C, Sterba J, van den Berg  H, Uttenreuther-Fischer M, Witt O, Norga K, Vassal G, on behalf of Members of Working Group 1 of the Paediatric Platform of ACCELERATE, Implementation of mechanism of action biology-driven early drug development for children with cancer. European Journal of Cancer 2016; 62  124- 131

Nailor A, Walker DA, Jacques TS, Warren KE, Brem H, Kearns PR, Greenwood J, Penny JI, Pilkington GJ, Carcaboso AM, Fleischhack G, Macarthur D, Slavc I, Meijer L, Gill S, Lowis S, van Vuurden DG, Pearl MS, Clifford SC, Morrissy S, Ivanov DP, Beccaria K, Gilbertson RJ, Straathof K, Green JJ, Smith S, Rahman R, Kilday JP. Highlights of Children with Cancer UK's Workshop on Drug Delivery in Paediatric Brain Tumour.Ecancermedicalscience. 2016 Mar 31;10:630.

Bautista F, Van der Lugt J, Kearns PR, Mussai FJ, Zwaan CM, Moreno L. The development of targeted new agents to improve the outcome for children with leukemia. Expert Opin Drug Discov. 2016 Nov;11(11):1111-1122.

Scholfield DW, Brundler MA, McDermott AL, Mussai F, Kearns P. Adjunctive Treatment in Juvenile Nasopharyngeal Angiofibroma: How Should We Approach Recurrence? J Pediatr Hematol Oncol. 2016 Apr;38(3):235-9.

Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell L, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C. The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukaemia blasts. Blood. 2016, Feb 11. pii: blood-2015-08-665034. [Epub ahead of print]

Main C, Wilson JS, Stevens SP, Houlton AE, English M, Kearns PR, Phillips B, Pizer B, Wilne S, Wheatley K. The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis. Syst Rev. 2015 Nov 20;4(1):168.

Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, U KP, Lo A, Ng M, Kearns P, Cheng P, De Santo C. Arginine dependence of Acute Myeloid Leukaemia blast proliferation: a novel therapeutic target. Blood 2015 Feb 20

Mussai FJ, Yap C, Mitchell C, Kearns P. Challenges of clinical trial design for targeted agents against pediatric leukemias. Front Oncol. 2015 Jan 6;4:374

Moroz V, Wilson JS, Kearns P, Wheatley K. Comparison of anticipated and actual control group outcome in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment. Trials.2014, 15:481

Thomas A, Perry T, Berhane S, Oldreive C, Zlatanou A, Williams LR, Weston VJ, Stankovic T, Kearns P, Pors K, Grand RJ, Stewart GS. The dual acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53, Oncogene 2014 1-14

Vassal G, Fitzgerald E, Schrappe M, Arnold F, Kowalczyk J, Walker D, Hjorth L, Riccardi E,  Kienesberger A, Pritchard-Jones K, Valsecchi MG, Janic D, Hasle H, Kearns P, Petrarulo G, Florindi F, Essiaf S, Ladenstein R. Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda. Paediatric Blood and Cancer 2014, Sep;61(9):1551-7

Leonard SM Perry T, Woodman C, Kearns P Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukaemia. 2014 PLoS One. 2014 Jan 28;9(1):e87475.

Kearns P, Morland B. New drug development in childhood cancer. Curr Opin Pediatr 2014, 26:37–42

Cader FZ, Vockerodt M, Bose S, Nagy E, Brundler MA, Kearns P, Murray PG. The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood. 2013 Dec 19;122(26):4237-45

Batra R, Abbott J, Jenkinson H, Ainsworth JR, Cole T, Parulekar MV, Kearns P. Long-term retinoblastoma follow-up with or without general anaesthesia. Pediatr Blood Cancer. 2014 Feb;61(2):260-4

Bailey S, Howman A, Wherton D,  Pizer B, Fisher D , Kearns P , Picton S , Saran F , Wheatley K, Gibson M, Glaser A, Connolly D, Hargrave D. Diffuse Intrinsic Pontine Glioma treated with prolonged temozolomide and radiotherapy – results of a United Kingdom Phase II Trial (CNS 2007 04) Eur J Cancer. 2013 Dec;49(18):3856-62

Da Costa D, Agathanggelou A, Perry T, Weston V, Petermann E, Zlatanou A, Oldreive C, Wei W, Stewart G, Longman J, Smith E, Kearns P, Knapp S, Stankovic T.  BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013 Jul 19;3:e126.

Kapatai G, Brundler MA, Jenkinson H, Kearns P, Parulekar M, Peet AC, McConville CM. Gene expression profiling identifies different sub-types of retinoblastoma. Br J Cancer. 2013 Jul 23;109(2):512-25.

Kearns P. The need for proportionate regulation of clinical trials. Lancet Oncol. 2013 May;14(6):454-5.

Zwaan CM, Rizzari C, Mechinaud F,  Lancaster DL,  Lehrnbecher T, van der Velden VHJ, Beverloo B,  den Boer ML, Pieters R, Reinhardt D, Dworzak M,  Rosenberg J, Manos G,  Agrawal S, Strauss L,  Baruchel A,  Kearns PR. Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180018 Phase I Dose-Escalation Study of the ‘Innovative Therapies for Children with Cancer’ Consortium.  J Clin Oncol. 2013 Jul 1;31(19):2460-8.

Irandoust M, Alvarez Zarate J, Hubeek I, van Beek EM, Schornagel K, Broekhuizen AJ, Akyuz M, van de Loosdrecht AA, Delwel R, Valk PJ, Sonneveld E, Kearns P, Creutzig U, Reinhardt D, de Bont ES, Coenen EA, van den Heuvel-Eibrink MM, Zwaan CM, Kaspers GJ, Cloos J, van den Berg TK. Engagement of SIRPα Inhibits Growth and Induces Programmed Cell Death in AML Cells. PLoS One. 2013;8(1):e52143.

Thompson CV, Wells JM, Bowen C, Brundler MA, Kearns P, Arul GS. Intra-abdominalkaposiform hemangioendothelioma and the benefits of laparoscopic surveillance. Pediatric Blood&Cancer 2012;58:992-3

GeoegerB, Estlin EJ, AertsI, Kearns P, Gibson B, Corradini N, Doz F, Lardelli P, Yovine  A, PradosR, Vassal G; on behalf of the European consortium Innovative Therapies for Children with Cancer (ITCC). A Phase I and Pharmacokinetic Study of Plitidepsin in Children with Advanced Solid Tumours: an Innovative Therapies for Children with Cancer (ITCC) study. European Journal of Cancer 2012 Feb;48(3):289-96